aldosterone and Metabolic Syndrome studies

Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.

Research Excerpts

Excerpt	Relevance	Reference
"Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome."	9.20	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. ( Bianchi, L; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D, 2015)
" Decreases in aldosterone were associated with decreases in C-reactive protein, leptin, insulin, homeostasis assessment of insulin resistance, heart rate, tonic cardiac sympathovagal balance and increases in adiponectin (all P<0."	9.17	Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. ( Barinas-Mitchell, E; Conroy, MB; Cooper, JN; Evans, RW; Fried, L; Mori Brooks, M; Sutton-Tyrrell, K; Tepper, P; Woodard, GA, 2013)
"The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome."	9.17	Effects of canrenone in patients with metabolic syndrome. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2013)
"This study was performed to determine the characteristics and mechanism of hypertension in SHR/NDmcr-cp(+/+) rats (SHRcp), a new model of metabolic syndrome, with a focus on the autonomic nervous system, aldosterone, and angiotensin II."	7.79	Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome--the critical role of angiotensin II. ( Kataoka, K; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Maeda, M; Matsui, K; Mingjie, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K; Waki, H; Yasuda, O, 2013)
"Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects."	7.79	Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013)
" It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension."	7.76	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010)
"In the present study, we assessed the levels of fasting homocysteine in patients with active Cushing's syndrome using two different assay methods."	7.74	Homocysteine, renin and aldosterone in patients with Cushing's syndrome. ( Elenkova, A; Kirilov, G; Lozanov, V; Mitev, V; Orbetzova, M; Shigarminova, R; Zacharieva, S, 2008)
"Aldosterone was in the past considered only as a prohypertensinogenic agent."	6.46	Aldosterone in uremia - beyond blood pressure. ( Koleganova, N; Ritz, E, 2010)
"Overweight and obesity are associated with arterial hypertension."	6.44	The association of aldosterone with obesity-related hypertension and the metabolic syndrome. ( Bochud, M; Burnier, M; Vogt, B, 2007)
"Metabolic syndrome is an aggregation of hypertension, diabetes and dyslipidaemia."	6.44	Aldosterone in salt-sensitive hypertension and metabolic syndrome. ( Fujita, T, 2008)
"Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here."	6.44	Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008)
"Aldosterone was associated with various markers of inflammation and metabolic dysregulation, which partly differed from the associations observed for renin."	5.56	Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020)
"Aldosterone has been linked with obesity, metabolic syndrome (MetS), pro-inflammatory, and prothrombotic states; however, most studies relate these indicators with primary aldosteronism (PA), excluding non-PA patients."	5.51	The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. ( Allende, F; Barros, ER; Baudrand, R; Campino, C; Carvajal, C; Fardella, CE; Fuentes, CA; García, H; Kalergis, AM; Martínez-Aguayo, A; Olmos, R; Solari, S; Tapia-Castillo, A; Vecchiola, A, 2019)
"We studied 66 patients with OSAHS (33 with MS and 33 without MS) and 35 controls."	5.40	Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. ( Alonso-Fernández, A; Arqué, M; Barbé, F; Barceló, A; Barceló, B; Bauçà, JM; de la Peña, M; Esquinas, C; Piérola, J; Robles, J, 2014)
"Aldosterone was positively associated with change in all MetS risk components, except low HDL cholesterol and waist circumference."	5.39	Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. ( Bidulescu, A; Fox, ER; Gawalapu, RK; Liu, J; Musani, SK; Samdarshi, TE; Sims, M; Steffes, M; Taylor, HA; Vasan, RS; Xanthakis, V, 2013)
"Metabolic syndrome is an important risk factor for proteinuria and chronic kidney disease independent of diabetes and hypertension; however, the underlying mechanisms have not been elucidated."	5.33	Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006)
"Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome."	5.20	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. ( Bianchi, L; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D, 2015)
" Decreases in aldosterone were associated with decreases in C-reactive protein, leptin, insulin, homeostasis assessment of insulin resistance, heart rate, tonic cardiac sympathovagal balance and increases in adiponectin (all P<0."	5.17	Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. ( Barinas-Mitchell, E; Conroy, MB; Cooper, JN; Evans, RW; Fried, L; Mori Brooks, M; Sutton-Tyrrell, K; Tepper, P; Woodard, GA, 2013)
"The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome."	5.17	Effects of canrenone in patients with metabolic syndrome. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2013)
" Subjects with the metabolic syndrome were treated with 0 mg of enalapril (n=9), 5 mg of enalapril (n=8), or 10 mg enalapril (n=7) after treatment with sitagliptin (100 mg/day for 5 days and matching placebo for 5 days) in a randomized, cross-over fashion."	5.14	Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. ( Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A, 2010)
"These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism."	3.85	Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder. ( Kim, IK; Olatunji, LA; Seok, YM; Usman, TO, 2017)
"Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects."	3.79	Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013)
"This study was performed to determine the characteristics and mechanism of hypertension in SHR/NDmcr-cp(+/+) rats (SHRcp), a new model of metabolic syndrome, with a focus on the autonomic nervous system, aldosterone, and angiotensin II."	3.79	Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome--the critical role of angiotensin II. ( Kataoka, K; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Maeda, M; Matsui, K; Mingjie, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K; Waki, H; Yasuda, O, 2013)
"We evaluated the circulating levels of resistin, leptin, and adiponectin, echocardiographic left ventricle (LV) parameters, and the prevalence of metabolic syndrome (SM) in subjects with PA."	3.76	Adipokines and cardiometabolic profile in primary hyperaldosteronism. ( Cianci, R; Cotesta, D; De Toma, G; Iacobellis, G; Letizia, C; Pergolini, M; Petramala, L; Sciomer, S; Zinnamosca, L, 2010)
" It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension."	3.76	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010)
"In the present study, we assessed the levels of fasting homocysteine in patients with active Cushing's syndrome using two different assay methods."	3.74	Homocysteine, renin and aldosterone in patients with Cushing's syndrome. ( Elenkova, A; Kirilov, G; Lozanov, V; Mitev, V; Orbetzova, M; Shigarminova, R; Zacharieva, S, 2008)
"Primary aldosteronism (PA) is the leading cause of curable endocrine hypertension, which is associated with a higher risk of cardiovascular and metabolic insults compared to essential hypertension."	3.01	Cardiovascular and metabolic characters of ( Chang, CC; Chang, YY; Chen, ZW; Chou, CH; Hung, CS; Lee, BC; Liao, CW; Lin, YH; Lu, CC; Pan, CT; Peng, KY; Tsai, CH; Wu, VC, 2023)
"Metabolic syndrome is a cluster of conditions that increase the risk of cardiovascular diseases, and comprises obesity, hypertension, impaired glucose metabolism and dyslipidaemia."	2.72	The mineralocorticoid receptor-an emerging player in metabolic syndrome? ( Stowasser, M; Thuzar, M, 2021)
"Aldosterone is a steroid hormone that regulates blood pressure and cardiovascular function by acting on renal and vascular mineralocorticoid receptors (MRs) to promote sodium retention and modulate endothelial function."	2.72	Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. ( Jia, G; Lockette, W; Sowers, JR, 2021)
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."	2.61	( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Aldosterone excess plays an important role in the association between resistant hypertension and obstructive sleep apnea."	2.58	Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. ( Calhoun, DA; Valaiyapathi, B, 2018)
"Patients with metabolic syndrome have higher aldosterone levels; moreover, an increased cardiometabolic risk associated with insulin resistance could be partially mediated by the action of aldosterone via mineralocorticoid receptors."	2.50	Aldosterone: a cardiometabolic risk hormone? ( Bressan, J; Eloiza Priore, S; Feliciano Pereira, P, 2014)
"Aldosterone was in the past considered only as a prohypertensinogenic agent."	2.46	Aldosterone in uremia - beyond blood pressure. ( Koleganova, N; Ritz, E, 2010)
"Aldosterone is an adrenal hormone that regulates sodium, fluid, and potassium balance."	2.45	Aldosterone and cardiovascular disease. ( Calhoun, DA; Gaddam, KK; Husain, S; Pimenta, E, 2009)
"Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here."	2.44	Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008)
"Overweight and obesity are associated with arterial hypertension."	2.44	The association of aldosterone with obesity-related hypertension and the metabolic syndrome. ( Bochud, M; Burnier, M; Vogt, B, 2007)
"Individuals with primary aldosteronism make up a substantial proportion of those with hypertension."	2.44	Hyperaldosteronism: a commonly occurring underlying feature of essential hypertension and the metabolic syndrome? ( Chun, TY; Pratt, JH, 2007)
"Aldosterone was also involved in the podocyte damage and proteinuria of metabolic syndrome model SHR/NDmcr-cp."	2.44	Aldosterone and glomerular podocyte injury. ( Fujita, T; Nagase, M, 2008)
"Metabolic syndrome is an aggregation of hypertension, diabetes and dyslipidaemia."	2.44	Aldosterone in salt-sensitive hypertension and metabolic syndrome. ( Fujita, T, 2008)
"Obesity is a common problem in much of the western world today in that is linked directly with several disease processes, notably, hypertension."	2.42	Hypertension and obesity. ( Aneja, A; El-Atat, F; McFarlane, SI; Sowers, JR, 2004)
"It showed that cardiac hypertrophy was associated with obesity while microalbuminuria was related to plasma aldosterone concentration (PAC) in PA patients."	1.72	Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome. ( Bu, X; He, H; Li, Y; Liu, X; Sun, F; Yan, Z; Zhang, H; Zhao, Z; Zhu, Z, 2022)
"Aldosterone was associated with various markers of inflammation and metabolic dysregulation, which partly differed from the associations observed for renin."	1.56	Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020)
"Patients with primary aldosteronism (PA) are complicated by metabolic syndrome more frequently than those without PA."	1.56	The risk factors for hepatic steatosis in patients with primary aldosteronism. ( Atsumi, T; Baba, S; Nakamura, A; Obara, S; Sakai, H; Shibayama, Y; Terae, S; Usubuchi, H; Wada, N, 2020)
"Aldosterone has been linked with obesity, metabolic syndrome (MetS), pro-inflammatory, and prothrombotic states; however, most studies relate these indicators with primary aldosteronism (PA), excluding non-PA patients."	1.51	The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. ( Allende, F; Barros, ER; Baudrand, R; Campino, C; Carvajal, C; Fardella, CE; Fuentes, CA; García, H; Kalergis, AM; Martínez-Aguayo, A; Olmos, R; Solari, S; Tapia-Castillo, A; Vecchiola, A, 2019)
"Metabolic syndrome is a major risk factor for the development of diabetes mellitus and cardiovascular diseases."	1.42	Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. ( Adler, GK; Alvarez de la Rosa, D; El Mogrhabi, S; Fallo, F; Feraco, A; Jaisser, F; Nguyen Dinh Cat, A; Quilliot, D; Rossignol, P; Sierra-Ramos, C; Touyz, RM; Urbanet, R; Venteclef, N, 2015)
"Primary aldosteronism (PA), the most frequent form of secondary hypertension, is characterized by a higher rate of cardiovascular (CV) events than essential hypertension (EH)."	1.40	Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. ( Boscaro, M; Ceccoli, L; di Tizio, V; Giacchetti, G; Ronconi, V; Turchi, F, 2014)
"We studied 66 patients with OSAHS (33 with MS and 33 without MS) and 35 controls."	1.40	Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. ( Alonso-Fernández, A; Arqué, M; Barbé, F; Barceló, A; Barceló, B; Bauçà, JM; de la Peña, M; Esquinas, C; Piérola, J; Robles, J, 2014)
"Humans with obesity and type 2 diabetes and KKAy and db/db mice were used to evaluate SGK1 expression in the adipose tissue of subjects with obesity and diabetes using quantitative real-time PCR and Western blot analysis."	1.39	SGK1 is regulated by metabolic-related factors in 3T3-L1 adipocytes and overexpressed in the adipose tissue of subjects with obesity and diabetes. ( Feng, W; Hao, Y; Li, P; Pan, F; Song, H; Zhu, D, 2013)
"Aldosterone was positively associated with change in all MetS risk components, except low HDL cholesterol and waist circumference."	1.39	Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. ( Bidulescu, A; Fox, ER; Gawalapu, RK; Liu, J; Musani, SK; Samdarshi, TE; Sims, M; Steffes, M; Taylor, HA; Vasan, RS; Xanthakis, V, 2013)
"She was diagnosed with combined primary hyperaldosteronism and Cushing's syndrome."	1.38	Combined aldosterone and cortisol secretion by adrenal incidentaloma. ( di Dalmazi, G; Giampalma, E; Golfieri, R; Marrano, N; Minni, F; Pasquali, R; Repaci, A; Rinaldi, E; Santini, D; Vicennati, V, 2012)
"Although nonalcoholic fatty liver disease (NAFLD) is considered a cardiometabolic risk factor, no data exist on its prevalence and clinical relevance in AI."	1.38	Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma. ( Alexandraki, K; Apostolopoulou, G; Chrousos, G; Kaltsas, G; Markou, A; Papanastasiou, L; Pappa, T; Piaditis, G; Samara, C; Tsiavos, V, 2012)
"Metabolic syndrome was defined according to ATPIII criteria."	1.36	Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. ( Agostinelli, L; Boscaro, M; Di Mattia, D; Giacchetti, G; Rilli, S; Ronconi, V; Turchi, F, 2010)
"Primary aldosteronism (PA) is a common form of secondary hypertension."	1.36	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. ( Dvoráková, J; Holaj, R; Masek, M; Petrák, O; Rosa, J; Somlóová, Z; Strauch, B; Vlková, J; Wichterle, D; Widimský, J; Zelinka, T, 2010)
"Metabolic syndrome is a highly predisposing condition for cardiovascular disease and could be a cause of excess salt-induced organ damage."	1.35	Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T, 2008)
"Hypertension was defined as average ambulatory blood pressure >130/85 mm Hg."	1.34	Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. ( Grim, CE; Kidambi, S; Kotchen, JM; Kotchen, TA; Mao, J; Raff, H; Singh, RJ, 2007)
"Forty patients with primary aldosteronism and 40 matched patients with low-renin essential hypertension (LREH) were studied."	1.34	Adiponectin and insulin sensitivity in primary aldosteronism. ( Bertello, C; Della Mea, P; Ermani, M; Fallo, F; Mulatero, P; Sonino, N; Veglio, F; Vettor, R, 2007)
"Metabolic syndrome is an important risk factor for proteinuria and chronic kidney disease independent of diabetes and hypertension; however, the underlying mechanisms have not been elucidated."	1.33	Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. ( Ando, K; Fujita, T; Gotoda, T; Nagase, M; Nagase, T; Shibata, S; Yoshida, S, 2006)
"Patients with adrenocortical adenoma have a significantly high prevalence of metabolic syndrome, especially the patients of CSA and NAA."	1.33	[Metabolic syndrome in patients with adrenocortical adenoma]. ( Ning, G; Tang, ZY; Wang, WQ; Zhang, W, 2006)

Research

Studies (101)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Change in MAP During Placebo

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	37 (36.63)	29.6817
2010's	54 (53.47)	24.3611
2020's	10 (9.90)	2.80

Authors	Studies
Bu, X	1
Sun, F	1
Zhang, H	2
Liu, X	1
Zhao, Z	2
He, H	1
Li, Y	5
Yan, Z	1
Zhu, Z	1
Chang, YY	1
Lee, BC	1
Chen, ZW	1
Tsai, CH	1
Chang, CC	1
Liao, CW	1
Pan, CT	1
Peng, KY	1
Chou, CH	1
Lu, CC	1
Wu, VC	1
Hung, CS	1
Lin, YH	1
Bobenko, AI	1
Heller, S	1
Schmitt, N	1
Cherdtrakulkiat, R	1
Lawung, R	1
Nabu, S	1
Tantimavanich, S	1
Sinthupoom, N	1
Prachayasittikul, S	1
Prachayasittikul, V	1
Zhang, B	1
Wu, C	1
Zhang, Z	3
Yan, K	1
Li, C	2
Li, L	3
Zheng, C	1
Xiao, Y	1
He, D	1
Zhao, F	1
Su, JF	1
Lun, SM	1
Hou, YJ	1
Duan, LJ	1
Wang, NC	1
Shen, FF	1
Zhang, YW	1
Gao, ZW	1
Li, J	5
Du, XJ	1
Zhou, FY	1
Yin, Z	1
Zhu, J	2
Yan, D	1
Lou, H	1
Yu, H	1
Feng, C	1
Wang, Z	2
Wang, Y	4
Hu, X	1
Li, Z	2
Shen, Y	1
Hu, D	1
Chen, H	1
Wu, X	1
Duan, Y	1
Zhi, D	1
Zou, M	2
Zhang, X	2
Yang, X	2
Zhang, J	2
Wang, H	1
Popović, KJ	1
Popović, DJ	1
Miljković, D	1
Lalošević, D	1
Čapo, I	1
Popović, JK	1
Liu, M	1
Song, H	3
Xing, Z	1
Lu, G	1
Chen, D	1
Valentini, AM	1
Di Pinto, F	1
Coletta, S	1
Guerra, V	1
Armentano, R	1
Caruso, ML	1
Gong, J	1
Wang, N	1
Bian, L	1
Wang, M	2
Ye, M	1
Wen, N	1
Fu, M	1
Fan, W	1
Meng, Y	1
Dong, G	1
Lin, XH	1
Liu, HH	1
Gao, DM	1
Cui, JF	1
Ren, ZG	1
Chen, RX	1
Önal, B	1
Özen, D	1
Demir, B	1
Akkan, AG	1
Özyazgan, S	1
Payette, G	1
Geoffroy, V	1
Martineau, C	1
Villemur, R	1
Jameel, T	1
Baig, M	1
Gazzaz, ZJ	1
Tashkandi, JM	1
Al Alhareth, NS	1
Khan, SA	1
Butt, NS	1
Wang, J	2
Geng, Y	1
Zhang, Y	3
Wang, X	2
Liu, J	3
Basit, A	1
Miao, T	1
Liu, W	1
Jiang, W	1
Yu, ZY	1
Wu, L	2
Qu, B	1
Sun, JX	1
Cai, AL	1
Xie, LM	1
Groeneveld, J	1
Ho, SL	1
Mackensen, A	1
Mohtadi, M	1
Laepple, T	1
Genovesi, S	1
Nava, E	1
Bartolucci, C	1
Severi, S	1
Vincenti, A	1
Contaldo, G	1
Bigatti, G	1
Ciurlino, D	1
Bertoli, SV	1
Slovak, JE	1
Hwang, JK	1
Rivera, SM	1
Villarino, NF	1
Li, S	1
Cao, G	1
Ling, M	1
Ji, J	1
Zhao, D	1
Sha, Y	1
Gao, X	1
Liang, C	2
Guo, Q	1
Zhou, C	1
Ma, Z	1
Xu, J	1
Wang, C	1
Zhao, W	1
Xia, X	1
Jiang, Y	1
Peng, J	1
Jia, Z	1
Li, F	1
Chen, X	2
Mo, J	1
Zhang, S	2
Li, X	1
Huang, T	1
Zhu, Q	1
Wang, S	1
Ge, RS	1
Fortunato, G	1
Lin, J	2
Agarwal, PK	1
Kohen, A	1
Singh, P	1
Cheatum, CM	1
Zhu, D	2
Hayman, A	1
Kebede, B	1
Stewart, I	1
Chen, G	1
Frew, R	1
Guo, X	1
Gong, Q	1
Borowiec, J	1
Han, S	1
Zhang, M	1
Willis, M	1
Kreouzis, T	1
Yu, K	1
Chirvony, VS	1
Sekerbayev, KS	1
Pérez-Del-Rey, D	1
Martínez-Pastor, JP	1
Palazon, F	1
Boix, PP	1
Taurbayev, TI	1
Sessolo, M	1
Bolink, HJ	1
Lu, M	1
Lan, Y	1
Xiao, J	1
Song, M	1
Chen, C	1
Huang, Q	1
Cao, Y	1
Ho, CT	1
Qi, B	1
Wang, Q	1
Zhang, W	2
Fang, L	1
Xie, CL	1
Chen, R	1
Yang, S	1
Xia, JM	1
Zhang, GY	1
Chen, CH	1
Yang, XW	1
Domenech-Ximenos, B	1
Garza, MS	1
Prat-González, S	1
Sepúlveda-Martínez, Á	1
Crispi, F	1
Perea, RJ	1
Garcia-Alvarez, A	1
Sitges, M	1
Kalumpha, M	1
Guyo, U	1
Zinyama, NP	1
Vakira, FM	1
Nyamunda, BC	1
Varga, M	1
Drácz, L	1
Kolbenheyer, E	1
Varga, F	1
Patai, ÁV	1
Solymosi, N	1
Patai, Á	1
Kiss, J	1
Gaál, V	1
Nyul, Z	1
Mosdósi, B	1
Valdez, M	1
Moosavi, L	1
Heidari, A	1
Novakovic-Agopian, T	1
Kornblith, E	1
Abrams, G	1
McQuaid, JR	1
Posecion, L	1
Burciaga, J	1
D'Esposito, M	1
Chen, AJW	1
Samy El Gendy, NM	1
Wesolowska, P	1
Georg, D	1
Lechner, W	1
Kazantsev, P	1
Bokulic, T	1
Tedgren, AC	1
Adolfsson, E	1
Campos, AM	1
Alves, VGL	1
Suming, L	1
Hao, W	1
Ekendahl, D	1
Koniarova, I	1
Bulski, W	1
Chelminski, K	1
Samper, JLA	1
Vinatha, SP	1
Rakshit, S	1
Siri, S	1
Tomsejm, M	1
Tenhunen, M	1
Povall, J	1
Kry, SF	1
Followill, DS	1
Thwaites, DI	1
Izewska, J	1
Kang, JH	1
Yoon, Y	1
Song, J	1
Van de Winckel, A	1
Gauthier, L	1
Chao, CT	1
Lee, YH	1
Li, CM	1
Han, DS	1
Huang, JW	1
Huang, KC	2
Ni, L	1
Güttinger, R	1
Triana, CA	1
Spingler, B	1
Baldridge, KK	1
Patzke, GR	1
Shen, X	1
Wang, B	1
Xie, S	1
Deng, W	1
Wu, D	1
Zhang, Q	1
Voskamp, BJ	1
Peelen, MJCS	1
Ravelli, ACJ	1
van der Lee, R	1
Mol, BWJ	1
Pajkrt, E	1
Ganzevoort, W	1
Kazemier, BM	1
Tibrewala, R	1
Bahroos, E	1
Mehrabian, H	1
Foreman, SC	1
Link, TM	1
Pedoia, V	1
Majumdar, S	1
Jablonski, CL	1
Leonard, C	1
Salo, P	1
Krawetz, RJ	1
Yoon, N	1
Hong, SN	1
Cho, JG	1
Jeong, HK	1
Lee, KH	1
Park, HW	1
Barman, S	1
Konai, MM	1
Samaddar, S	1
Haldar, J	1
Mohamed, HSH	1
Li, CF	1
Hu, ZY	1
Deng, Z	1
Chen, LH	1
Su, BL	1
Chu, K	1
Liu, YP	1
Li, YB	1
Xu, C	1
Zou, Z	1
Wu, Z	1
Xia, Y	1
Zhao, P	1
Wang, HT	1
de Biase, S	1
Pellitteri, G	1
Gigli, GL	1
Valente, M	1
Shibayama, Y	1
Wada, N	1
Baba, S	1
Obara, S	1
Sakai, H	1
Usubuchi, H	1
Terae, S	1
Nakamura, A	1
Atsumi, T	1
van der Heijden, CDCC	1
Ter Horst, R	1
van den Munckhof, ICL	1
Schraa, K	1
de Graaf, J	1
Joosten, LAB	1
Danser, AHJ	1
Netea, MG	1
Deinum, J	1
Rutten, J	1
Riksen, NP	1
Luo, Q	1
Tuersun, T	1
Wang, G	1
Wu, T	1
Zhang, D	1
Zhou, K	1
Sun, L	1
Yue, N	1
Li, N	1
Zhang, SL	1
Gao, JW	1
Guo, Y	1
Feng, QL	1
Tang, JY	1
Yan, L	1
Wang, JF	1
Cheng, H	1
Liu, PM	1
Ayuzawa, N	1
Fujita, T	14
Jia, G	1
Lockette, W	1
Sowers, JR	6
Thuzar, M	1
Stowasser, M	1
Valaiyapathi, B	1
Calhoun, DA	2
Cannone, V	1
Buglioni, A	1
Sangaralingham, SJ	1
Scott, C	1
Bailey, KR	1
Rodeheffer, R	1
Redfield, MM	1
Sarzani, R	1
Burnett, JC	1
Vecchiola, A	1
Fuentes, CA	1
Barros, ER	1
Martínez-Aguayo, A	1
García, H	1
Allende, F	1
Solari, S	1
Olmos, R	1
Carvajal, C	1
Tapia-Castillo, A	1
Campino, C	2
Kalergis, AM	2
Baudrand, R	2
Fardella, CE	2
Bothou, C	1
Beuschlein, F	2
Spyroglou, A	1
Williams, JS	1
Gamliel-Lazarovich, A	1
Raz-Pasteur, A	1
Coleman, R	1
Keidar, S	1
Carvajal, CA	1
Olivieri, O	1
Guidi, G	1
Faccini, G	1
Vöhringer, PA	1
Cerda, J	1
Owen, G	1
Long, HD	1
Lin, YE	1
Liu, MJ	1
Liang, LY	1
Zeng, ZH	1
Sueta, D	1
Kataoka, K	1
Koibuchi, N	1
Toyama, K	1
Uekawa, K	1
Katayama, T	1
Mingjie, M	1
Nakagawa, T	1
Waki, H	1
Maeda, M	1
Yasuda, O	1
Matsui, K	1
Ogawa, H	1
Kim-Mitsuyama, S	1
Cooper, JN	1
Fried, L	1
Tepper, P	1
Barinas-Mitchell, E	1
Conroy, MB	1
Evans, RW	1
Mori Brooks, M	1
Woodard, GA	1
Sutton-Tyrrell, K	1
Musani, SK	1
Vasan, RS	2
Bidulescu, A	1
Xanthakis, V	1
Sims, M	1
Gawalapu, RK	1
Samdarshi, TE	1
Steffes, M	1
Taylor, HA	1
Fox, ER	1
Derosa, G	2
Bonaventura, A	1
Bianchi, L	2
Romano, D	2
D'Angelo, A	2
Fogari, E	1
Maffioli, P	2
Li, P	1
Pan, F	1
Hao, Y	1
Feng, W	1
Kawarazaki, W	1
Barceló, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579]	Phase 4	8,000 participants (Anticipated)	Interventional	2023-04-16	Enrolling by invitation
A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095]		30 participants (Actual)	Interventional	2020-08-16	Completed
Clinical Trial to Reverse Early Arterial Stiffening[NCT00366990]		349 participants (Actual)	Interventional	2007-01-31	Completed
Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218]		0 participants	Observational	2007-11-30	Recruiting
The Evaluation of Renal Denervation on Several Biological Variables in Patients With Uncontrolled Hypertension. An Observational Feasibility Study.[NCT01427049]		54 participants (Actual)	Observational	2011-08-31	Completed
Prospective Cross-sectional Study on Prevalence of Primary Aldosteronism in Resistant Hypertension and Association With Cardiometabolic Complications[NCT04213963]		100 participants (Anticipated)	Observational	2011-09-01	Recruiting
Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome[NCT00666848]	Phase 4	24 participants (Actual)	Interventional	2008-03-31	Completed
Genetic Based Analysis of Identifying Predictors of Blood Pressure Response in Hypertensive Patients After Renal Denervation[NCT04321044]		300 participants (Actual)	Interventional	2019-01-01	Active, not recruiting
Salt Sensitive Hypertension and Striatin[NCT03683069]	Phase 4	400 participants (Actual)	Interventional	2019-01-15	Active, not recruiting
BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects[NCT01977859]	Phase 1	4 participants (Actual)	Interventional	2013-11-30	Completed
Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects[NCT03234751]	Phase 1	6 participants (Actual)	Interventional	2017-07-13	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo (NCT00666848)
Timeframe: just prior to drug administration and 8 hours after drug administration

Change in MAP During Sitagliptin

Intervention	mmHg (Mean)
2 (Enalapril 5mg)	-0.9
1 (Placebo)	2.7
3 (Enalapril 10mg)	-7.9

Mean change in mean arterial pressure in response to placebo or enalapril in the presence of 5 days of sitagliptin 100mg/day (NCT00666848)
Timeframe: just prior to drug administration and 8 hours following treatment

Article	Year
Cardiovascular and metabolic characters of Frontiers in endocrinology, 2023, Volume: 14 Topics: Adenoma; Adrenocortical Adenoma; Aldosterone; Female; G Protein-Coupled Inwardly-Rectifying Potassiu	2023
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P	2019
The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury. Journal of the American Society of Nephrology : JASN, 2021, Volume: 32, Issue:2 Topics: Acute Kidney Injury; Aldosterone; Humans; Hypertension; Metabolic Syndrome; Receptors, Mineralocorti	2021
Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. American journal of physiology. Regulatory, integrative and comparative physiology, 2021, 03-01, Volume: 320, Issue:3 Topics: Aldosterone; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin	2021
The mineralocorticoid receptor-an emerging player in metabolic syndrome? Journal of human hypertension, 2021, Volume: 35, Issue:2 Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Metabolic Syndrome; Mineralocorticoid Recepto	2021
Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Current hypertension reports, 2018, 03-19, Volume: 20, Issue:3 Topics: Aldosterone; Humans; Hyperaldosteronism; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists;	2018
Links between aldosterone excess and metabolic complications: A comprehensive review. Diabetes & metabolism, 2020, Volume: 46, Issue:1 Topics: Aldosterone; Blood Glucose; Diabetes Complications; Humans; Hyperaldosteronism; Insulin; Insulin Res	2020
Evolving research in nongenomic actions of aldosterone. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:3 Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Cell Membrane; Humans; Metabol	2013
Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension. Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:12 Topics: Aldosterone; Animals; Humans; Hypertension; Kidney; Metabolic Syndrome; rac1 GTP-Binding Protein; Ra	2013
Clock genes in hypertension: novel insights from rodent models. Blood pressure monitoring, 2014, Volume: 19, Issue:5 Topics: Aldosterone; Animals; ARNTL Transcription Factors; Blood Vessels; Circadian Rhythm; CLOCK Proteins;	2014
Aldosterone: a cardiometabolic risk hormone? Nutricion hospitalaria, 2014, Dec-01, Volume: 30, Issue:6 Topics: Aldosterone; Cardiovascular Diseases; Diet; Humans; Metabolic Diseases; Metabolic Syndrome; Obesity;	2014
Recent topics on podocytes and aldosterone. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2015, Volume: 25, Issue:2 Topics: Aldosterone; Animals; Disease Models, Animal; Humans; Hypertension; Metabolic Syndrome; Mice; Podocy	2015
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circulation research, 2015, Mar-13, Volume: 116, Issue:6 Topics: Aldosterone; Animals; Antihypertensive Agents; Dyslipidemias; Heart Conduction System; Hemodynamics;	2015
Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders. Current hypertension reports, 2015, Volume: 17, Issue:7 Topics: Aldosterone; Cardiovascular Diseases; Humans; Hypertension; Metabolic Syndrome; Obesity; Receptors,	2015
The adipose tissue and the involvement of the renin-angiotensin-aldosterone system in cardiometabolic syndrome. Cell and tissue research, 2016, Volume: 366, Issue:3 Topics: Adipose Tissue; Aldosterone; Animals; Humans; Metabolic Syndrome; Renin-Angiotensin System	2016
[System renin-aldosterone in fat tissue and other organ and tissues]. Vnitrni lekarstvi, 2008, Volume: 54, Issue:5 Topics: Adipose Tissue; Aldosterone; Humans; Hypertension; Metabolic Syndrome; Obesity; Renin	2008
Obesity, sleep apnea, aldosterone, and hypertension. Current hypertension reports, 2008, Volume: 10, Issue:3 Topics: Aldosterone; Humans; Hypertension; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesi	2008
Aldosterone and CKD in metabolic syndrome. Current hypertension reports, 2008, Volume: 10, Issue:6 Topics: Albuminuria; Aldosterone; Biomarkers; Female; Humans; Kidney Failure, Chronic; Male; Metabolic Syndr	2008
Aldosterone and cardiovascular disease. Current problems in cardiology, 2009, Volume: 34, Issue:2 Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular	2009
Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? Journal of hypertension, 2009, Volume: 27, Issue:7 Topics: Aldosterone; Angiotensins; Blood Pressure; Heart Failure; Humans; Kidney; Metabolic Syndrome; Renin;	2009
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of internal medicine, 2009, Jun-02, Volume: 150, Issue:11 Topics: Aldosterone; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hypertension; Insulin Resistanc	2009
Mineralocorticoid receptor activation in obesity hypertension. Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:8 Topics: Aldosterone; Animals; Biological Evolution; Humans; Hypertension; Ligands; Metabolic Syndrome; Miner	2009
Mineralocorticoid receptors in the metabolic syndrome. Trends in endocrinology and metabolism: TEM, 2009, Volume: 20, Issue:9 Topics: Aldosterone; Animals; Glucocorticoids; Humans; Metabolic Syndrome; Mineralocorticoids; Models, Biolo	2009
Aldosterone and cardiovascular risk. Current hypertension reports, 2009, Volume: 11, Issue:6 Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins;	2009
Aldosterone in uremia - beyond blood pressure. Blood purification, 2010, Volume: 29, Issue:2 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Endothelial Cells; Endothelium, Vascular;	2010
Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:4 Topics: Aldosterone; Animals; Humans; Hypertension; Metabolic Syndrome; Rats; Rats, Inbred Dahl; Receptors,	2010
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system]. Nihon Jinzo Gakkai shi, 2010, Volume: 52, Issue:2 Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mine	2010
Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:6 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Resistance; Dru	2010
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clinical and experimental nephrology, 2010, Volume: 14, Issue:4 Topics: Aldosterone; Animals; Chronic Disease; Disease Models, Animal; Enzyme Inhibitors; Humans; Hypertensi	2010
Mineralocorticoid receptor antagonists and the metabolic syndrome. Current hypertension reports, 2010, Volume: 12, Issue:4 Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resist	2010
The role of aldosterone in the metabolic syndrome. Current hypertension reports, 2011, Volume: 13, Issue:2 Topics: Aldosterone; Cardiovascular System; Humans; Inflammation; Insulin Resistance; Lipids; Metabolic Synd	2011
Aldosterone, hypertension, and beyond. Iranian journal of kidney diseases, 2011, Volume: 5, Issue:2 Topics: Aldosterone; Epigenomics; Epithelial Sodium Channels; Humans; Hyperaldosteronism; Hypertension; Hypo	2011
Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Molecular and cellular endocrinology, 2012, Mar-24, Volume: 350, Issue:2 Topics: Aldosterone; Animals; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Models, Biological; Rats;	2012
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Current vascular pharmacology, 2012, Volume: 10, Issue:2 Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Progression; Endothelium, Vascular; Humans; I	2012
Primary aldosteronism and metabolic syndrome. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2012, Volume: 44, Issue:3 Topics: Aldosterone; Animals; Glucose; Humans; Hyperaldosteronism; Insulin; Metabolic Syndrome	2012
Extrarenal effects of aldosterone. Current opinion in nephrology and hypertension, 2012, Volume: 21, Issue:2 Topics: Aldosterone; Endothelium, Vascular; Heart; Humans; Hypertension; Inflammation; Metabolic Syndrome; M	2012
[Kidney diseases and mineralocorticoid receptor]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Nov-10, Volume: 98, Issue:11 Topics: Aldosterone; Animals; Humans; Kidney Diseases; Metabolic Syndrome; Mineralocorticoid Receptor Antago	2009
Vascular actions of aldosterone. Journal of vascular research, 2013, Volume: 50, Issue:2 Topics: Adipocytes; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Vessels; Cardiovasc	2013
Hypertension and obesity. Recent progress in hormone research, 2004, Volume: 59 Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R	2004
Hypertension and obesity. Recent progress in hormone research, 2004, Volume: 59 Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R	2004
Hypertension and obesity. Recent progress in hormone research, 2004, Volume: 59 Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R	2004
Hypertension and obesity. Recent progress in hormone research, 2004, Volume: 59 Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R	2004
[Metabolic syndrome and aldosterone]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Sep-10, Volume: 95, Issue:9 Topics: Aldosterone; Animals; Humans; Intra-Abdominal Fat; Kidney Glomerulus; Metabolic Syndrome; Obesity; O	2006
The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Seminars in nephrology, 2007, Volume: 27, Issue:5 Topics: Adipose Tissue; Aldosterone; Animals; Blood Pressure; Humans; Hypertension; Metabolic Syndrome; Obes	2007
[Hypertension and metabolic syndrome]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Sep-10, Volume: 96, Issue:9 Topics: Aldosterone; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Oxidative Stress; Renin-A	2007
Hyperaldosteronism: a commonly occurring underlying feature of essential hypertension and the metabolic syndrome? Current opinion in endocrinology, diabetes, and obesity, 2007, Volume: 14, Issue:3 Topics: Aldosterone; Black or African American; Humans; Hyperaldosteronism; Hypertension; Insulin Resistance	2007
Aldosterone and glomerular podocyte injury. Clinical and experimental nephrology, 2008, Volume: 12, Issue:4 Topics: Aldosterone; Animals; Disease Models, Animal; Humans; Hypertension; Metabolic Syndrome; Oxidative St	2008
Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:5 Topics: Aldosterone; Cardiovascular Diseases; Humans; Hypertension; Lipid Metabolism; Metabolic Syndrome; Ob	2008
Adrenal steroids and the metabolic syndrome. Current hypertension reports, 2007, Volume: 9, Issue:6 Topics: Adrenal Cortex Hormones; Adrenal Glands; Aldosterone; Bone Diseases, Metabolic; Cushing Syndrome; En	2007
Aldosterone in salt-sensitive hypertension and metabolic syndrome. Journal of molecular medicine (Berlin, Germany), 2008, Volume: 86, Issue:6 Topics: Aldosterone; Animals; Humans; Hypertension; Metabolic Syndrome; Receptors, Mineralocorticoid; Renin-	2008
Adrenocortical dysfunction in obesity and the metabolic syndrome. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2008, Volume: 40, Issue:8 Topics: Adrenal Cortex; Adrenal Medulla; Aldosterone; Humans; Metabolic Syndrome; Obesity	2008

Article	Year
Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:10 Topics: Adiponectin; Adiposity; Adult; Aldosterone; Blood Pressure; C-Reactive Protein; Diet, Sodium-Restric	2013
Effects of canrenone in patients with metabolic syndrome. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:16 Topics: Aged; Aldosterone; Blood Glucose; Blood Pressure; C-Reactive Protein; Canrenone; Female; Humans; Ins	2013
The effects of canrenone on inflammatory markers in patients with metabolic syndrome. Annals of medicine, 2015, Volume: 47, Issue:1 Topics: Aged; Aldosterone; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Canrenon	2015
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:4 Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabete	2010

Article	Year
Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome. Journal of diabetes research, 2022, Volume: 2022 Topics: Albuminuria; Aldosterone; Cardiomegaly; Carotid Intima-Media Thickness; Glucose; Humans; Hyperaldost	2022
The risk factors for hepatic steatosis in patients with primary aldosteronism. Endocrine journal, 2020, Jun-29, Volume: 67, Issue:6 Topics: Adult; Aldosterone; Blood Pressure; Fatty Liver; Female; Humans; Hyperaldosteronism; Hypertension; I	2020
Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. The Journal of clinical endocrinology and metabolism, 2020, 08-01, Volume: 105, Issue:8 Topics: Aged; Aged, 80 and over; Aldosterone; Atherosclerosis; Biomarkers; Carotid Arteries; Cross-Sectional	2020
Higher prevalence of metabolic disorders in patients with bilateral primary aldosteronism than unilateral primary aldosteronism. Clinical endocrinology, 2021, Volume: 94, Issue:1 Topics: Adrenal Glands; Aldosterone; Humans; Hyperaldosteronism; Metabolic Syndrome; Prevalence; Retrospecti	2021
Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism. Frontiers in endocrinology, 2020, Volume: 11 Topics: Adult; Aldosterone; Asian People; Case-Control Studies; China; Essential Hypertension; Female; Human	2020
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clinic proceedings, 2018, Volume: 93, Issue:8 Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L	2018
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clinic proceedings, 2018, Volume: 93, Issue:8 Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L	2018
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clinic proceedings, 2018, Volume: 93, Issue:8 Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L	2018
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clinic proceedings, 2018, Volume: 93, Issue:8 Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L	2018
The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. American journal of hypertension, 2019, 04-22, Volume: 32, Issue:5 Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; Cross-Sectional Studies; Disease Progression; Female	2019
The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:9 Topics: Adrenalectomy; Aldosterone; Animals; Blood Glucose; Blood Pressure; Cells, Cultured; Cholesterol; Di	2013
High sodium intake is associated with increased glucocorticoid production, insulin resistance and metabolic syndrome. Clinical endocrinology, 2014, Volume: 80, Issue:5 Topics: Adiponectin; Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Blood Glucose; Body Mass Index	2014
Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. Journal of endocrinological investigation, 2013, Volume: 36, Issue:11 Topics: Aldosterone; Animals; Apoptosis; Diet, High-Fat; Dyslipidemias; Hypertension; Insulin-Secreting Cell	2013
Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome--the critical role of angiotensin II. Journal of the American Heart Association, 2013, Apr-29, Volume: 2, Issue:3 Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Circadian Rhythm; Disease Models, Animal; Hype	2013
Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes care, 2013, Volume: 36, Issue:10 Topics: Adult; Aged; Aldosterone; C-Reactive Protein; Female; Humans; Male; Metabolic Syndrome; Middle Aged;	2013
SGK1 is regulated by metabolic-related factors in 3T3-L1 adipocytes and overexpressed in the adipose tissue of subjects with obesity and diabetes. Diabetes research and clinical practice, 2013, Volume: 102, Issue:1 Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Aldosterone; Animals; Diabetes Mellitus, Type 2; Humans; I	2013
Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PloS one, 2014, Volume: 9, Issue:1 Topics: Adult; Aldosterone; Continuous Positive Airway Pressure; Humans; Male; Metabolic Syndrome; Middle Ag	2014
Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:5 Topics: Adult; Aged; Aldosterone; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Essential Hyperten	2014
Higher blood aldosterone level in metabolic syndrome is independently related to adiposity and fasting plasma glucose. Cardiovascular diabetology, 2015, Jan-13, Volume: 14 Topics: Adiponectin; Adiposity; Aldosterone; Biomarkers; Blood Glucose; Cross-Sectional Studies; Fasting; Fe	2015
Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:1 Topics: 3T3-L1 Cells; Adipocytes, White; Aldosterone; Animals; Cell Line, Tumor; Dibenzocycloheptenes; Enzym	2015
Maternal and Fetal Outcomes in Preeclampsia: Interrelations Between Insulin Resistance, Aldosterone, Metabolic Syndrome, and Polycystic Ovary Syndrome. Journal of clinical hypertension (Greenwich, Conn.), 2015, Volume: 17, Issue:10 Topics: Aldosterone; Female; Humans; Hypertension; Insulin; Insulin Resistance; Metabolic Syndrome; Polycyst	2015
Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance. American journal of physiology. Renal physiology, 2016, 05-01, Volume: 310, Issue:9 Topics: Aldosterone; Animals; Blood Pressure; Circadian Rhythm; Diet, High-Fat; Epithelial Sodium Channels;	2016
Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder. Archives of physiology and biochemistry, 2017, Volume: 123, Issue:1 Topics: Aldosterone; Animals; Ataxia Telangiectasia Mutated Proteins; Cardiovascular Diseases; Contraceptive	2017
Adipocyte-Specific Mineralocorticoid Receptor Overexpression in Mice Is Associated With Metabolic Syndrome and Vascular Dysfunction: Role of Redox-Sensitive PKG-1 and Rho Kinase. Diabetes, 2016, Volume: 65, Issue:8 Topics: Adipocytes; Aldosterone; Angiotensin II; Animals; Cells, Cultured; Corticosterone; Culture Media, Co	2016
Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. American journal of hypertension, 2008, Volume: 21, Issue:9 Topics: Adult; Aldosterone; Blood Pressure; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Lef	2008
Homocysteine, renin and aldosterone in patients with Cushing's syndrome. Methods and findings in experimental and clinical pharmacology, 2008, Volume: 30, Issue:3 Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; C	2008
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:2 Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Dopple	2008
Canonical transient receptor potential channels expression is elevated in a porcine model of metabolic syndrome. Molecular endocrinology (Baltimore, Md.), 2009, Volume: 23, Issue:5 Topics: Adrenal Medulla; Aldosterone; Animals; Biological Transport; Calcium; Cells, Cultured; Chromaffin Ce	2009
Hypertension, insulin resistance, and aldosterone: sex-specific relationships. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:3 Topics: Adolescent; Adult; Age Factors; Aldosterone; Anthropometry; Black or African American; Blood Glucose	2009
Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2010, Volume: 20, Issue:2 Topics: Adiponectin; Aldosterone; Biomarkers; Blood Glucose; Chi-Square Distribution; Cross-Sectional Studie	2010
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. Journal of human hypertension, 2010, Volume: 24, Issue:6 Topics: Aged; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A	2010
Hypovolaemia-induced metabolic dysfunction, mediated in part by aldosterone and angiotensin. Journal of hypertension, 2009, Volume: 27, Issue:10 Topics: Aldosterone; Angiotensins; Humans; Hypertension; Hypovolemia; Metabolic Syndrome; Renin-Angiotensin	2009
Adipokines and cardiometabolic profile in primary hyperaldosteronism. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:5 Topics: Adenoma; Adiponectin; Adult; Aged; Aldosterone; Biomarkers; Blood Glucose; Blood Pressure; C-Reactiv	2010
The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of human hypertension, 2010, Volume: 24, Issue:10 Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Biomarkers; Blood Pressure; Body Mass Index; C	2010
Metabolic syndrome and primary aldosteronism: time for reappraisal? Journal of human hypertension, 2010, Volume: 24, Issue:10 Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Biomarkers; Blood Pressure; Body Mass Index; Humans;	2010
Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. Pharmacogenetics and genomics, 2011, Volume: 21, Issue:6 Topics: Aldosterone; Blood Pressure; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Hemodynamics; Huma	2011
Association of plasma aldosterone with the metabolic syndrome in two German populations. European journal of endocrinology, 2011, Volume: 164, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Female; Follow-Up Studies; Germany; Health	2011
Combined aldosterone and cortisol secretion by adrenal incidentaloma. International journal of surgical pathology, 2012, Volume: 20, Issue:3 Topics: Adrenal Gland Neoplasms; Aged; Aldosterone; Cushing Syndrome; Diabetes Mellitus, Type 2; Female; Hum	2012
In utero and neonate exposure to nonylphenol develops hyperadrenalism and metabolic syndrome later in life. I. First generation rats (F(1)). Toxicology, 2012, Nov-15, Volume: 301, Issue:1-3 Topics: Adipose Tissue; Adrenocortical Hyperfunction; Adrenocorticotropic Hormone; Aldosterone; Animals; Bod	2012
Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma. European journal of clinical investigation, 2012, Volume: 42, Issue:11 Topics: Adrenal Gland Neoplasms; Aldosterone; Anthropometry; Body Mass Index; Case-Control Studies; Fatty Li	2012
Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension (Dallas, Tex. : 1979), 2013, Volume: 61, Issue:4 Topics: Aldosterone; Cross-Sectional Studies; Female; Humans; Hypertension; Incidence; Male; Metabolic Syndr	2013
Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:2 Topics: Africa, Eastern; Aldosterone; Blood Pressure; Female; Humans; Male; Metabolic Syndrome; Middle Aged;	2006
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Topics: Adipocytes; Adrenal Glands; Aldosterone; Animals; Cyclic N-Oxides; Disease Models, Animal; Eplerenon	2006
Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:3 Topics: Adolescent; Adult; Aldosterone; Black People; Female; Humans; Hydrocortisone; Hypertension; Male; Me	2007
[Metabolic syndrome in patients with adrenocortical adenoma]. Zhonghua yi xue za zhi, 2006, Dec-26, Volume: 86, Issue:48 Topics: Adrenocortical Adenoma; Adrenocorticotropic Hormone; Aldosterone; Blood Glucose; Body Size; China; F	2006
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007, Volume: 21, Issue:9 Topics: Adipocytes, White; Adipogenesis; Adipose Tissue, White; Aldosterone; Animals; Cell Differentiation;	2007
Adiponectin and insulin sensitivity in primary aldosteronism. American journal of hypertension, 2007, Volume: 20, Issue:8 Topics: Adiponectin; Aldosterone; Biomarkers; Female; Follow-Up Studies; Humans; Hyperaldosteronism; Insulin	2007
Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation, 2007, Aug-28, Volume: 116, Issue:9 Topics: Aldosterone; Biomarkers; Blood Circulation; Blood Glucose; C-Reactive Protein; Cardiovascular Diseas	2007
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5 Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertensio	2007
Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity. Journal of human hypertension, 2008, Volume: 22, Issue:2 Topics: Adolescent; Albuminuria; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Ma	2008
New trends in insulin resistance: the role of mineralocorticoids. Journal of the cardiometabolic syndrome, 2007,Fall, Volume: 2, Issue:4 Topics: Aldosterone; Animals; Humans; Insulin Resistance; Metabolic Syndrome; Mineralocorticoids; Oxidative	2007
Aldosterone and hypertension in the cardiometabolic syndrome. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:2 Topics: Aldosterone; Body Mass Index; Humans; Hyperaldosteronism; Hypertension; Metabolic Syndrome; Risk Fac	2008

aldosterone and Metabolic Syndrome